CoChat

Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome

Open access
Sturm, Theo, Sautter, Benedikt, Wörner, Tobias P., Stevanović, Stefan, Rammensee, Hans-Georg, Planz, Oliver, Heck, Albert J. R., Aebersold, Ruedi · 2021 · Journal of Proteome Research

The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index; none of the 98 sources its claims cite is checked for support yet.

Abstract

To understand and treat immunology-related diseases, a comprehensive, unbiased characterization of major histocompatibility complex (MHC) peptide ligands is of key importance. Preceding the analysis by mass spectrometry, MHC class I peptide ligands are typically isolated by MHC immunoaffinity chromatography (MHC-IAC) and less often by mild acid elution (MAE). MAE may provide a cheap alternative to MHC-IAC for suspension cells but has been hampered by the high number of contaminating, MHC-unrelated peptides. Here, we optimized MAE, yielding MHC peptide ligand purities of more than 80%. When compared with MHC-IAC, obtained peptides were similar in numbers, identities, and to a large extent intensities, while the percentage of cysteinylated peptides was 5 times higher in MAE. The latter benefitted the discovery of MHC-allotype-specific, distinct cysteinylation frequencies at individual positions of MHC peptide ligands. MAE revealed many MHC ligands with unmodified, N-terminal cysteine residues which get lost in MHC-IAC workflows. The results support the idea that MAE might be particularly valuable for the high-confidence analysis of post-translational modifications by avoiding the exposure of the investigated peptides to enzymes and reactive molecules in the cell lysate. Our improved and carefully documented MAE workflow represents a high-quality, cost-effective alternative to MHC-IAC for suspension cells.

Overview

CoChat Summary

TL;DR

Optimized mild acid elution (MAE) yields HLA class I peptide purities above 80% and peptide numbers, identities, and MS1 intensities largely comparable to MHC immunoaffinity chromatography (MHC-IAC). MAE recovers about 5-fold more cysteinylated peptides and better preserves N-terminal unmodified cysteine residues, making it a cost-effective alternative for suspension cells, though it remains unsuitable for solid tissue or frozen cells.

Key findings

  • Optimized MAE achieved >80% MHC peptide ligand purity; >82% of identified 8–12-mers were assigned to an appropriate MHC allotype using NetMHC IC50 <500 nM. MAE yielded 9% (JY) to 30% (THP-1) fewer peptides than MHC-IAC. Of 2072 total JY peptides, 50% were found by both methods; of 1268 THP-1 peptides, 36% were shared. Strong binders overlapped 55% (JY) and 41% (THP-1), while putative contaminants overlapped only 17% (JY, 32/189) and 7% (THP-1, 12/168).
  • Quantitative MS1 data correlated between MAE and MHC-IAC with R² = 0.65 (JY) and R² = 0.62 (THP-1); 69.3% and 63.2% of shared peptides differed by less than 2-fold in mean MS1 intensity. The overall median MS1 intensity of identified MHC ligands differed by less than 2% between extraction methods.
  • MAE showed on average >5-fold higher relative cysteinylated peptides than MHC-IAC: mean 2.91% vs 0.53% (P = 2.6 × 10⁻⁶). Cysteinylation was enriched among HLA-A*02:01 binders and diminished among HLA-B*07:02 binders; preferred at position C-1 for both allotypes, and at C-4 for HLA-A*02:01 but not HLA-B*07:02. MAE also revealed carbamidomethylated N-terminal cysteine residues.
  • In MHC-IAC, acetonitrile-based ultrafilter rinsing yielded 2–3 times more peptide identifications and boosted MS1 intensities 27-fold and 41-fold versus the first ultrafiltrate, especially for hydrophobic peptides. Repeated MAE recovered only 2.1% and 3.5% of peptides relative to the first MAE, indicating acidic elution was nearly complete; <2% of cells survived the repeated MAE.

Methods

  • Direct comparison of optimized MAE and MHC-IAC starting from the same cell cultures, primarily JY and THP-1 suspension cells (LCL5 also described in Methods). MAE used 5 × 10⁸ JY cells and 1.25 × 10⁸–1.5 × 10⁹ THP-1 cells; MHC-IAC used W6/32 for HLA-A, -B, -C and L243/Tü39 for MHC-II.
  • Peptides were analyzed by LC-MS/MS on an LTQ Orbitrap XL and an Orbitrap Fusion. Data were processed with Proteome Discoverer, Mascot/Sequest, and Percolator with a peptide spectral match FDR ≤5%; searches allowed 8–12-mers and variable modifications including oxidation, cysteinylation, and carbamidomethylation.
  • Analyses included peptide overlap, MS1 intensity correlation, MHC allotype assignment via NetMHC/Syfpeithi, positional cysteinylation frequencies, repeated MAE, organic-solvent elution tests, and acetonitrile ultrafilter rinsing. Structural exposure measures used selected HLA-A*02:01 and HLA-B*07:02 PDB crystal structures.

Limitations

  • Stated: MAE is not applicable to solid tissue, appears unsuitable for frozen cells, and cannot sample MHC-II; MHC-IAC remains necessary for solid tissues and frozen cells. Repeated MAE is not beneficial because it causes substantial cellular stress, with <2% cell survival.
  • Stated: the relative contribution of W6/32 antibody bias versus sample-processing bias could not be deduced from this study, and additional studies are needed. The structural explanation for cysteinylation patterns remains a hypothesis requiring crystal structures with cysteinylated MHC peptide ligands. HLA-B*07:02 structural analysis was limited by only four PDB entries, two of which were putatively not representative.
  • Evident from the text: the main comparison focused on two suspension cell lines and a limited set of HLA allotypes; MHC-IAC was deliberately performed without cysteine protection for representativeness, which may affect cysteine-related comparisons. MAE by design samples only cell-surface MHC-I and excludes intracellular MHC compartments.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1021/acs.jproteome.0c00386

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 2 Not valid · 61 Not checked · 171 Own results and interpretations

153 more claims

Create a free account to see all 234 claims and to verify the 96 references still open.

See all claims — free account
  • It may state two separate claims as one. 45
  • The quote only partly states this claim. 2
  • Probably not a substantial claim. 34

Create a free account to see these claims.

Citations

Cites

Show all 71 references

Cited by

See all 63

Metadata

Authors
Sturm, T., Sautter, B., Wörner, T. P., Stevanović, S., Rammensee, H.-G., Planz, O., Heck, A. J. R., & Aebersold, R.
Affiliations
  • Utrecht University (NL)
  • University of Tübingen (DE)
  • Utrecht University , , ,
  • University of Tübingen , , ,
  • University of Zurich (CH)
Corresponding author
  • Sturm, Theo
  • Aebersold, Ruedi
Venue
Journal of Proteome Research
Published
2020-11-03
Volume
20
Issue
1
Pages
289-304
ISSN
  • 1535-3893 (ISSN-L)
  • 1535-3907
OpenAlex
W3097954807
Cited by
63
References
71
Citations by year
2026: 12 · 2025: 6 · 2024: 14 · 2023: 12 · 2022: 12 · 2021: 7
FWCI
1.98
Type
journal article
Language
en
Open access
Locations
  • Journal of Proteome Research (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Repository for Publications and Research Data (ETH Zurich) (publishedVersion, cc-by-nc-nd)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
  • ETH Zürich Research Collection (cc-by-nc-nd)
Funders
  • Horizon 2020 Framework Programme (2-73838-14)
  • H2020 European Research Council (670821, ERC-2008-AdG_20080422)
  • H2020 Future and Emerging Technologies (686547)
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (3100A0-688 107679)
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek (SPI.2017.028)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
  • Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
  • Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
Keywords
immunopeptidome, cysteine modification, post-translational modification, peptide purification, suspension-cultured cells
MeSH terms
Chromatography, Affinity, Cysteine, Peptides, Protein Binding, Mass Spectrometry, Histocompatibility Antigens Class I

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.